Hormone replacement therapy
Malignant neoplasm of the breast - Hormone replacement therapy Factor
Last reviewed for CCPS 05 October 2006.
Preliminary questions [23825]
21468 there is some evidence that hormone replacement therapy may be a factor in the development of the condition under consideration.
1169 — the veteran is a woman.
the veteran has had hormone replacement therapy at some time.8816 — the veteran has established the causal connection between the hormone replacement medication and VEA service for the clinical onset of malignant neoplasm of the breast.
8820 — the veteran has established the causal connection between the hormone replacement medication and eligible service for the clinical onset of malignant neoplasm of the breast.
or
8819 — the veteran has established the causal connection between the hormone replacement medication and operational service for the clinical onset of malignant neoplasm of the breast.
Clinical onset and operational service [8819]
the veteran had hormone replacement therapy for at least two years before the clinical onset of malignant neoplasm of the breast. the veteran's hormone replacement therapy for at least two years was materially contributed to by treatment of an illness or injury which is identifiable. the veteran's hormone replacement therapy for at least two years before the clinical onset of malignant neoplasm of the breast was materially contributed to by treatment of the identified illness or injury. where treatment of the identified illness or injury materially contributed to the veteran's hormone replacement therapy for at least two years before the clinical onset of malignant neoplasm of the breast, the hormone replacement therapy continued to within the ten years before the clinical onset of the condition under consideration.8823 — the identified illness or injury, for which the veteran had hormone replacement therapy, is causally related to operational service.
Clinical onset and eligible service [8820]
the veteran had hormone replacement therapy for at least four years before the clinical onset of malignant neoplasm of the breast. the veteran's hormone replacement therapy for at least two years was materially contributed to by treatment of an illness or injury which is identifiable. the veteran's hormone replacement therapy for at least four years before the clinical onset of malignant neoplasm of the breast was materially contributed to by treatment of the identified illness or injury. where treatment of the identified illness or injury materially contributed to the veteran's hormone replacement therapy for at least four years before the clinical onset of malignant neoplasm of the breast, the hormone replacement therapy continued to within the five years before the clinical onset of the condition under consideration.8824 — the identified illness or injury, for which the veteran had hormone replacement therapy, is causally related to eligible service.
Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/m/malignant-neoplasm-breast-b019-c50d05/rulebase-malignant-neoplasm-breast/hormone-replacement-therapy